MannKind Corporation (FRA:NNFN)

Market Cap	1.54B
Revenue (ttm)	267.44M
Net Income (ttm)	24.92M
Shares Out	n/a
EPS (ttm)	0.08
PE Ratio	61.98
Forward PE	30.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	5.09
Previous Close	4.91
Day's Range	5.09 - 5.09
52-Week Range	2.93 - 5.97
Beta	n/a
RSI	62.59
Earnings Date	Feb 23, 2026

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipelin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 407
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NNFN

Financial Performance

Financial numbers in USD